Project Elevator Pitch
Confidential · For registered investors
Issued
2026-05-30
ARS
Panama · Agri
Aqua Farming | Panama
Agri
Food Manufacturing, Production & Distribution
Fisheries/Fish Farming
Capital Sought
USD 150,000,000
Spent to date
USD 2,000,000
Country
Panama
Repayment
Other Off-Take Agreement
Submission Ready Indicators
LTV Expectation
95%
Land / Site
Sale/lease agreed
EPC Contracts
Completed awaiting signature
Off-take Agreements
Completed awaiting signature
Projections
Completed and available
This opportunity qualifies for Internationally A+-rated Insurance Wrap — elevating the debt element of project financing through the Lloyds-of-London insurance market.
About this opportunity
ARS is requesting US$127M to build a state-of-the-art aquaponics (dual aquaculture) facility that will serve as a model of sustainability and productivity for the future of the entire industry.
This facility will be located on the Panamanian Atlantic coast, adjacent to the sea, where weather patterns are stable and reliable and where the water is clean.
American Red Snapper was chosen as the featured species due to its hardiness and exceptionally low mortality rates as compared to other species, its favored fish status in American and Asian markets, and its favorable ratio of demand to historically low availability as the wild Red Snapper is excessively regulated.
This operation will raise the American Red Snapper from eggs and hatchlings to a marketable center of the plate size. ARS will generate several streams of revenue by growing, processing, and shipping fresh, frozen, and live fish while culturing Spirulina, a blue-green algae used as a nutritional supplement globally and manufactured on-site.
This well-planned complex will utilize a highly accomplished team of aquaculture scientists, highly experienced fish farm operators, a seasoned seafood industry management team, and local labor, providing much-needed jobs to the native Panama community.
Five-year projections
All figures in USD| USD | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Turnover | 18,310,616 | 73,242,463 | 183,106,157 | 329,591,082 | 329,591,082 |
| EBITDA | 3,075,692 | 40,702,150 | 157,948,759 | 238,604,820 | 238,604,820 |
| Margin % | 16.8 | 55.6 | 86.2 | 72.4 | 72.4 |
Ready to learn more?
The full executive summary and data room are available to PFX registered investors.
Register as Investor
Executive summaries can be viewed by registered PFX Investors. Already registered? Sign in.
Confidential — PFX Registered Investors Only · Not for redistribution
PFX / ARS / 2026-05-30